A phase I study to evaluate the safety, tolerability, and pharmacokinetics of HEC113995PA·H2O, a novel dual-acting serotonergic antidepressant, in healthy subjects

A phase I study to evaluate the safety, tolerability, and pharmacokinetics of HEC113995PA·H2O, a novel dual-acting serotonergic antidepressant, in healthy subjects

PurposeHEC113995PA·H2O is a novel, potent and selective serotonin (5-HT) reuptake inhibitor and a 5-HT1A receptor partial agonist, and thus is categorized as a serotonin partial agonist-reuptake inhibitor. The objective of this study was to evaluate the safety, tolerability, and pharmacokinetics of...

Full description

Saved in:
Bibliographic Details
Main Authors: Xue Wu, Qingqing Wu, Qichen Ding, Yulei Zhuang, Lin Luo, Yingjun Zhang, Li Deng, Chuanfei Jin, Xue Li, Zhangma Huang, Haiping Qin, Liang Xin, Qian Chen, Jingying Jia, Yanmei Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Pharmacology
Subjects:
HEC113995PA
H2O
SPARI
safety
pharmacokinetics
food effect
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1500974/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1500974/full

Similar Items